PMID- 2569215
OWN - NLM
STAT- MEDLINE
DCOM- 19890829
LR  - 20190726
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 98
IP  - 2
DP  - 1989
TI  - Behavioral effects of (+-) 3,4-methylenedioxyamphetamine (MDA) and (+-) 
      3,4-methylenedioxymethamphetamine (MDMA) in the pigeon: interactions with 
      noradrenergic and serotonergic systems.
PG  - 183-8
AB  - The effects of three amphetamine analogs were assessed in pigeons key pecking 
      under a multiple 3-min fixed-interval (FI), 30 response fixed-ratio (FR) schedule 
      of food presentation. At doses between 0.1 and 10.0 mg/kg, (+-) 
      3,4-methylenedioxyamphetamine (MDA), (+-) 3,4-methylenedioxymethamphetamine 
      (MDMA), and (+-)-N-ethyl-3,4-methylenedioxyamphetamine (MDE) either had no effect 
      or decreased response rates in both components of the multiple schedule in a 
      dose-dependent manner. MDA was at least 1 log unit more potent than the other two 
      compounds. Metergoline (0.1-1.0 mg/kg), a serotonin (5-HT) antagonist with 
      comparable affinity for the 5-HT1 and 5-HT2 receptor subtypes, blocked the 
      rate-decreasing effects of 3.0 mg/kg MDA in both components of the multiple 
      schedule, but did not affect the MDMA dose-response curve. The 5-HT2 receptor 
      antagonist ketanserin (0.1-3.0 mg/kg) also restored FI and FR responding that was 
      decreased by 3.0 mg/kg MDA, but had no effect on responding suppressed by MDMA. 
      The noradrenergic alpha-1 antagonist prazosin (0.3-3.0 mg/kg) blocked the 
      behavioral effects of 3.0 mg/kg MDMA at doses that did not attenuate MDA's 
      rate-decreasing effects. These results indicate that although MDA and MDMA are 
      structurally similar and have similar behavioral effects, their actions appear to 
      be mediated through different neurotransmitter systems.
FAU - Nader, M A
AU  - Nader MA
AD  - Behavioral Pharmacology Laboratory, Department of Psychiatry, Uniformed Services 
      University of the Health Sciences, Bethesda, MD 20814-4799.
FAU - Hoffmann, S M
AU  - Hoffmann SM
FAU - Barrett, J E
AU  - Barrett JE
LA  - eng
GR  - DA-02873/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Amphetamines)
RN  - 1501393LY5 (Metergoline)
RN  - 333DO1RDJY (Serotonin)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 97F9DE4CT4 (Ketanserin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - ML1I4KK67B (3,4-methylenedioxyethamphetamine)
RN  - X4W3ENH1CV (Norepinephrine)
RN  - XM03YJ541D (Prazosin)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/analogs & derivatives/*pharmacology
MH  - Amphetamines/*pharmacology
MH  - Animals
MH  - Behavior, Animal/*drug effects
MH  - Columbidae
MH  - Conditioning, Operant/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Ketanserin/pharmacology
MH  - Male
MH  - Metergoline/pharmacology
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Norepinephrine/physiology
MH  - Prazosin/pharmacology
MH  - Reinforcement Schedule
MH  - Serotonin/*physiology
MH  - Sympathetic Nervous System/*physiology
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1007/BF00444689 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 1989;98(2):183-8. doi: 10.1007/BF00444689.